Tag:
taspoglutide
Latest Headlines
Latest Headlines
GSK's albiglutide flunks head-to-head diabetes PhIII with rival Victoza
GlaxoSmithKline ( $GSK ) has stumbled badly in its first late-stage study of albiglutide, a weekly GLP-1 diabetes drug. Reporting on the top-line results for the first of eight Phase III studies
Roche dumps taspoglutide as analysts read last rites
Roche is cutting its losses on the once-promising diabetes drug taspoglutide , returning the rights it had licensed from Ipsen after the therapy was torpedoed in late-stage trials by unexpected side
Roche spotlights top late-stage drug prospects in pipeline review
What's Roche willing to bet hundreds of millions of dollars on next year? This morning the pharma giant answered that question by highlighting its 14 late-stage prospects in the pipeline, promising
Roche, Ipsen diabetes drug sidelined by PhIII safety issues
After stumbling badly on troubling safety data in June , researchers handling the late-stage diabetes study of taspoglutide have run straight into a brick wall. Ipsen and Roche say they have opted to
Analysts turn bearish on Roche's taspoglutide prospects
After initially tapping taspoglutide as the latest in a string of likely blockbusters-to-be from Roche, analysts are turning sour on the drug's prospects after gaining a close look at the side effect
Roche faces long delay for diabetes drug taspoglutide
Roche has delayed development of its potential blockbuster type 2 diabetes drug taspoglutide for up to 18 months due to hypersensitivity problems observed in trial subjects, including skin reactions
Rival developers race to grab Type 2 diabetes market
If the FDA approves the once-weekly diabetes treatment exenatide (Bydureon) later this year, it may quickly face some strong competition from new drugs now in the pipeline, according to a review
Roche's taspoglutide gins blockbuster diabetes data in PhIII
Roche ( NASDAQ: RHHBY ) took another big stride today in its long march toward a regulatory filing for the likely diabetes blockbuster taspoglutide. The pharma giant said that the experimental medicine
Roche diabetes drug performs like a blockbuster in Ph3
Roche says that its experimental Type 2 diabetes drug taspoglutide looked effective, safe and was well tolerated in five late-stage trials. Investigators say that the data demonstrated that the
Roche diabetes drug beats Januvia in Phase III
Roche rolled out data from a pair of Phase III trials of its experimental diabetes drug taspoglutide, saying that researchers have nailed down its superiority to Merck's blockbuster Januvia. The
